 Antimetabolites, Antineoplastic
"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antimetabolites that are useful in cancer chemotherapy.
| Descriptor ID |
D000964
|
| MeSH Number(s) |
D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".
This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in this website by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 2 | 4 | | 2010 | 0 | 1 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 2 | 3 | | 2014 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.
-
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 01 20; 139(3):413-423.
-
Cojocaru E, Thway K, Fisher C, Messiou C, Zaidi S, Miah AB, Benson C, Gennatas S, Huang P, Jones RL. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Res. 2020 Dec; 40(12):7003-7007.
-
Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 07 15; 125(14):2445-2454.
-
Mittal N, Li L, Sheng Y, Hu C, Li F, Zhu T, Qiao X, Qian Z. A critical role of epigenetic inactivation of miR-9 in EVI1high pediatric AML. Mol Cancer. 2019 02 27; 18(1):30.
-
Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, Fisher C, Zaidi S, Miah A, Judson I, van der Graaf W, Keedy VL, Benson C, Jones RL. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018 Aug 20; 35(10):131.
-
Cheng J, Wang Y, Zhang CF, Wang H, Wu WZ, Pan F, Hong N, Deng J. Chemotherapy response evaluation in a mouse model of gastric cancer using intravoxel incoherent motion diffusion-weighted MRI and histopathology. World J Gastroenterol. 2017 Mar 21; 23(11):1990-2001.
-
Lee YY, Li CF, Lin CY, Lee SW, Sheu MJ, Lin LC, Chen TJ, Wu TF, Hsing CH. Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. Tumour Biol. 2014 Nov; 35(11):11097-105.
-
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, Macdonald J, Willett CG. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 =90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e291-7.
-
Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
-
Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|